July 8, 2020 / 6:45 AM / a month ago

UPDATE 1-AstraZeneca-Merck's Lynparza wins EU approval for pancreatic cancer

(Adds details on treatment, background)

July 8 (Reuters) - AstraZeneca Plc and Merck & Co Inc said on Wednesday their blockbuster cancer treatment Lynparza won approval in the European Union for treating patients with a form of pancreatic cancer.

The approval was based on results from a late-stage trial in which Lynparza nearly doubled the lifespan of patients without disease progression or death when compared with placebo.

Lynparza, which can now be used to treat patients with a form of BRCA-mutated metastatic pancreatic cancer, leads a class of drugs known as PARP inhibitors that stop cancer cells from repairing themselves after being damaged by chemotherapy.

The approval comes more than a month after the drug received positive recommendation from the European Medicines Agency for the same indication.

Lynparza became the first marketed PARP drug with a U.S. approval for ovarian cancer in 2014 and is key to AstraZeneca's push in oncology and sustaining the company's turnaround.

In 2018, about 460,000 people were diagnosed with pancreatic cancer, a rare, life-threatening disease with the lowest survival rate among patients with most common cancers, the company said. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Anil D'Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below